What sector does DAEWOONG PHARMA belong to?

DAEWOONG PHARMA operates in the Pharmaceuticals sector, specifically the Pharmaceuticals industry, and is listed on the US markets.

What is the current share price of 069620?

As of the latest available quote, 069620 traded at ₩111,900.00. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of 069620?

DAEWOONG PHARMA has a price-to-earnings (P/E) ratio of about 6.57. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of 069620?

The market capitalisation of DAEWOONG PHARMA is approximately ₩1.27T.

Is DAEWOONG PHARMA profitable?

For its latest reported financial year, DAEWOONG PHARMA recorded a net profit margin of about 12.28%.

Does 069620 pay a dividend?

DAEWOONG PHARMA currently has a dividend yield of about 0.30%.

What is the return on equity (ROE) of 069620?

DAEWOONG PHARMA has a return on equity (ROE) of about 19.47%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of 069620?

Over the past 52 weeks, 069620 has traded between a low of ₩105,000.00 and a high of ₩199,400.00.

DAEWOONG PHARMA

069620 KRX Pharmaceuticals Pharmaceuticals

KOSPI

₩111,900.00

-1.15%

Delayed · cached 15 min

Fair value analysis

069620

DAEWOONG PHARMA

₩111,900.00

Close used for this calculation

₩319,540.33Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

65/100

Profitability21/25

Returns19/25

Balance Sheet3/25

Efficiency22/25

Growth20/25

Strong

Quality radar

Consensus fair value

₩319,540.33

Below FV

▲ +185.6% against the close used

Model range ₩182,981.26 – ₩1,100,756.00

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₩182,981.26Fair value₩319,540.33Bull₩1,100,756.00

FairClose

52-week traded range

52W low ₩107,300.0052W high ₩194,000.00

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading below the consensus fair value

DAEWOONG PHARMA closed at ₩111,900.00, 65.0% below the consensus fair value of ₩319,540.33 drawn from 9 valuation models.

Financial DNA score 65/100 — Strong. P/E of 6.6x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

₩337,870.00

+201.9%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

₩182,981.26

+63.5%

√(22.5 × EPS × BVPS)

EPS=17022, BVPS=87421.88

Graham Formula

₩1,100,756.00

+883.7%

EPS × (8.5 + 2g) × 4.4 ÷ FD_Rate

g=20%, FD=3.3%

P/E Fair Value

₩340,440.00

+204.2%

EPS × 20x (sector P/E)

EPS=17022, Sector P/E=20x

Peter Lynch (PEG)

₩510,660.00

+356.4%

EPS × Growth% (PEG = 1 is fair)

EPS=17022, g=30%

EV/EBITDA

₩306,298.42

+173.7%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=196.78B

Book Value (P/B)

₩294,393.16

+163.1%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=87421.88, ROE=19.5%, g=6%, r=10%

Reverse DCF

₩111,900.00

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: -8.3% | Historical: 37.2%

Margin of Safety

₩367,883.86

+228.8%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=490511.82, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer